WO2018194380A3 - Lrig-1 단백질에 특이적인 결합 분자 및 이의 용도 - Google Patents

Lrig-1 단백질에 특이적인 결합 분자 및 이의 용도 Download PDF

Info

Publication number
WO2018194380A3
WO2018194380A3 PCT/KR2018/004523 KR2018004523W WO2018194380A3 WO 2018194380 A3 WO2018194380 A3 WO 2018194380A3 KR 2018004523 W KR2018004523 W KR 2018004523W WO 2018194380 A3 WO2018194380 A3 WO 2018194380A3
Authority
WO
WIPO (PCT)
Prior art keywords
lrig
binding molecule
protein
present
cells
Prior art date
Application number
PCT/KR2018/004523
Other languages
English (en)
French (fr)
Other versions
WO2018194380A2 (ko
Inventor
김정호
김범석
Original Assignee
주식회사 굳티셀
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 굳티셀 filed Critical 주식회사 굳티셀
Priority to CA3064852A priority Critical patent/CA3064852A1/en
Priority to AU2018256237A priority patent/AU2018256237A1/en
Priority to CN201880025794.3A priority patent/CN110799534B/zh
Priority to JP2019556608A priority patent/JP7276858B6/ja
Priority to US16/606,220 priority patent/US11279756B2/en
Priority to EP18787597.6A priority patent/EP3613772A4/en
Publication of WO2018194380A2 publication Critical patent/WO2018194380A2/ko
Publication of WO2018194380A3 publication Critical patent/WO2018194380A3/ko
Priority to US17/672,208 priority patent/US11999785B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

본 발명은 조절 T 세포의 표면에 존재하는 단백질인 Lrig-1 단백질에 특이적으로 결합할 수 있는 결합 분자에 관한 것이다. 본 발명에서 제공하는 결합 분자는, 조절 T 세포의 기능을 활성화하여 다양한 면역 세포 및 염증 세포들의 과도화된 활성화 및 발현에 의하여 유도되는 질환으로, 예를 들면, 자가면역질환, 이식편대숙주 질환, 장기이식거부반응, 천식, 아토피, 또는 급성 또는 만성의 염증 질환 등의 면역 관련 질환을 효과적으로 예방, 개선 또는 치료할 수 있다. 또한, 본 발명에 따른 Lrig-1 단백질에 특이적인 결합 분자, 바람직하게 항체는, 기존에 상업적으로 판매되고 있던 Lrig-1에 대한 항체와 비교할 때 Lrig-1 단백질에 더욱 효과적으로 표적화 할 수 있고, 결합력 또한 매우 우수한 장점이 있다.
PCT/KR2018/004523 2017-04-18 2018-04-18 Lrig-1 단백질에 특이적인 결합 분자 및 이의 용도 WO2018194380A2 (ko)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA3064852A CA3064852A1 (en) 2017-04-18 2018-04-18 Binding molecule specific for lrig-1 protein and use thereof
AU2018256237A AU2018256237A1 (en) 2017-04-18 2018-04-18 Binding molecule specific for Lrig-1 protein and use thereof
CN201880025794.3A CN110799534B (zh) 2017-04-18 2018-04-18 Lrig-1蛋白的特异性结合分子及其用途
JP2019556608A JP7276858B6 (ja) 2017-04-18 2018-04-18 Ｌｒｉｇ‐１タンパク質に特異的な結合分子およびその用途
US16/606,220 US11279756B2 (en) 2017-04-18 2018-04-18 Binding molecule specific for LRIG-1 protein and use thereof
EP18787597.6A EP3613772A4 (en) 2017-04-18 2018-04-18 SPECIFIC BINDING MOLECULE FOR LRIG-1 PROTEIN AND ITS USE
US17/672,208 US11999785B2 (en) 2017-04-18 2022-02-15 Binding molecule specific for Lrig-1 protein and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170049854 2017-04-18
KR10-2017-0049854 2017-04-18

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/606,220 A-371-Of-International US11279756B2 (en) 2017-04-18 2018-04-18 Binding molecule specific for LRIG-1 protein and use thereof
US17/672,208 Continuation US11999785B2 (en) 2017-04-18 2022-02-15 Binding molecule specific for Lrig-1 protein and use thereof

Publications (2)

Publication Number Publication Date
WO2018194380A2 WO2018194380A2 (ko) 2018-10-25
WO2018194380A3 true WO2018194380A3 (ko) 2019-04-11

Family

ID=63856720

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/KR2018/004524 WO2018194381A1 (ko) 2017-04-18 2018-04-18 Lrig-1 단백질에 특이적인 결합 분자 및 이의 용도
PCT/KR2018/004523 WO2018194380A2 (ko) 2017-04-18 2018-04-18 Lrig-1 단백질에 특이적인 결합 분자 및 이의 용도

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/004524 WO2018194381A1 (ko) 2017-04-18 2018-04-18 Lrig-1 단백질에 특이적인 결합 분자 및 이의 용도

Country Status (8)

Country Link
US (2) US11365249B2 (ko)
EP (2) EP3613772A4 (ko)
JP (2) JP7276858B6 (ko)
KR (2) KR102086649B1 (ko)
CN (2) CN110799534B (ko)
AU (1) AU2018256237A1 (ko)
CA (1) CA3064852A1 (ko)
WO (2) WO2018194381A1 (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11365249B2 (en) 2017-04-18 2022-06-21 Good T Cells, Inc. Binding molecule specific for Lrig-1 protein and use thereof
KR102275514B1 (ko) * 2018-05-09 2021-07-09 주식회사 굳티셀 조절 t 세포 표면 항원의 에피토프 및 이에 특이적으로 결합하는 항체
EP3868782A1 (en) * 2018-10-17 2021-08-25 Good T Cells, Inc. Binding molecule specific to lrig-1 protein, and use thereof
EP3943107A4 (en) * 2019-03-20 2022-12-07 Good T Cells, Inc. COMPOSITION FOR PREVENTING OR TREATING DISEASE OF THE BRAIN AND NERVOUS SYSTEM
WO2021006714A1 (ko) * 2019-07-11 2021-01-14 주식회사 굳티셀 면역체크포인트 억제제 저항성 암의 예방, 개선 또는 치료용 조성물
CN114929733A (zh) * 2019-11-08 2022-08-19 古德T细胞有限公司 调节性t细胞表面抗原的表位和与其特异性结合的抗体
CN116444660A (zh) * 2020-05-19 2023-07-18 益科思特(北京)医药科技发展有限公司 抗新型冠状病毒Spike蛋白抗体及其应用
KR20220053723A (ko) * 2020-10-22 2022-05-02 주식회사 굳티셀 활성화된 면역 세포의 세포 표면 항원 및 이의 다양한 용도
WO2022131889A1 (ko) 2020-12-16 2022-06-23 주식회사 굳티셀 Taci 단백질의 용도
BR112023015002A2 (pt) * 2021-01-27 2023-12-05 Good T Cells Inc Nova molécula de ligação e uso da mesma
KR20230016148A (ko) * 2021-07-16 2023-02-01 주식회사 굳티셀 조절 t 세포 표면 항원의 에피토프 및 이에 특이적으로 결합하는 항체

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120041139A (ko) * 2010-10-20 2012-04-30 주식회사 한독약품 인간 인터루킨-1 수용체 길항제-하이브리드 Ｆｃ 융합단백질
KR20120085593A (ko) * 2011-01-24 2012-08-01 연세대학교 산학협력단 조절자 Ｔ 세포에 특이적으로 존재하는 새로운 표면단백질 Ｌｒｉｇ-1의 용도
US20150086553A1 (en) * 2013-09-10 2015-03-26 Samsung Electronics Co., Ltd. Polypeptide binding to annexin a1 and use thereof
WO2015187359A1 (en) * 2014-06-04 2015-12-10 Ngm Biopharmaceuticals, Inc. Compositions and methods for targeting a pathway

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
US6046030A (en) * 1997-09-22 2000-04-04 Smithkline Beecham Corporation Human LIG-1 homolog (HLIG-1)
US20060204503A1 (en) 2005-01-31 2006-09-14 Biogen Idec Ma Inc. Treatment of cancer using antibodies to polypeptides differentially expressed in human lung tumors
EP1997832A1 (en) * 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
KR101938699B1 (ko) * 2012-07-23 2019-01-16 삼성전자주식회사 Ｌｒｉｇ１의 항 ｃ―ｍｅｔ 항체 적용 대상 환자 선별을 위한 용도
KR102060540B1 (ko) 2013-04-03 2019-12-31 삼성전자주식회사 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물
US11365249B2 (en) 2017-04-18 2022-06-21 Good T Cells, Inc. Binding molecule specific for Lrig-1 protein and use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120041139A (ko) * 2010-10-20 2012-04-30 주식회사 한독약품 인간 인터루킨-1 수용체 길항제-하이브리드 Ｆｃ 융합단백질
KR20120085593A (ko) * 2011-01-24 2012-08-01 연세대학교 산학협력단 조절자 Ｔ 세포에 특이적으로 존재하는 새로운 표면단백질 Ｌｒｉｇ-1의 용도
US20150086553A1 (en) * 2013-09-10 2015-03-26 Samsung Electronics Co., Ltd. Polypeptide binding to annexin a1 and use thereof
WO2015187359A1 (en) * 2014-06-04 2015-12-10 Ngm Biopharmaceuticals, Inc. Compositions and methods for targeting a pathway

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE GenBank 1 June 2015 (2015-06-01), "Immunoglobulin Light Chain Constant Region Kappa, Partial [ Mus musculus", XP055590135, Database accession no. CAC20700.1 *
DATABASE GenBank 26 July 2016 (2016-07-26), "Immunoglobulin Kappa Chain V-J-C, Partial [Homo sapiens", XP055590145, Database accession no. AAA59000.1 *
DATABASE GenBank 27 April 1993 (1993-04-27), "IgG [Homo sapiens", XP055590140, Database accession no. AAA02914.1 *
DATABASE protein 24 July 2016 (2016-07-24), "Immunoglobulin Heavy Chain, Partial [Mus musculus", XP055590128, Database accession no. AAN86780.1 *

Also Published As

Publication number Publication date
CN110945024B (zh) 2023-05-12
CN110945024A (zh) 2020-03-31
JP2020517241A (ja) 2020-06-18
WO2018194381A1 (ko) 2018-10-25
EP3613771A4 (en) 2021-08-04
KR20180117067A (ko) 2018-10-26
JP7276858B6 (ja) 2023-06-09
JP2020517248A (ja) 2020-06-18
EP3613772A2 (en) 2020-02-26
US20200048343A1 (en) 2020-02-13
US20200131261A1 (en) 2020-04-30
EP3613771A1 (en) 2020-02-26
WO2018194380A2 (ko) 2018-10-25
CA3064852A1 (en) 2018-10-25
EP3613772A4 (en) 2020-12-30
JP7276858B2 (ja) 2023-05-18
AU2018256237A1 (en) 2019-12-05
CN110799534A (zh) 2020-02-14
US20220251189A1 (en) 2022-08-11
JP7276859B2 (ja) 2023-05-18
CN110799534B (zh) 2023-05-12
US11365249B2 (en) 2022-06-21
US11279756B2 (en) 2022-03-22
JP7276859B6 (ja) 2023-06-09
KR102086649B1 (ko) 2020-04-23
KR102086656B1 (ko) 2020-03-10
KR20180117066A (ko) 2018-10-26

Similar Documents

Publication Publication Date Title
WO2018194380A3 (ko) Lrig-1 단백질에 특이적인 결합 분자 및 이의 용도
PH12018501080A1 (en) Pd1 and/or lag3 binders
PH12018501778A1 (en) Antibodies to tigit
SG10201907215QA (en) Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof
NZ734803A (en) Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
EA201490745A1 (ru) Полипептиды антител, которые вызывают антагонизм cd40l
CA2868907C (en) Anti-hla-b*27 antibodies and uses thereof
WO2019224716A8 (en) Antibodies specific for gucy2c and uses thereof
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
MY189590A (en) Ctla4 binders
WO2015073884A3 (en) Glycoengineered antibody compositions
MX2021011633A (es) Metodos para reducir los niveles de suero de agentes que contienen fc que usan antagonistas de fcrn.
WO2016201124A3 (en) T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla
JOP20180117B1 (ar) أجسام مضادة انتقائية لـ tau فائق المعالجة بفوسفوريلات وطرق لاستخدامها
SG10201804513WA (en) Antibodies Against Fcrn And Use Thereof
GB2509260A (en) Anti-complement C1s antibodies and uses thereof
MX2018009011A (es) Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos.
BR112019008702A2 (pt) polipeptídeo, método de diminuição de uma função fc efetora de um polipeptídeo, composição, método de tratamento, kit de partes, e, uso de um polipeptídeo ou composição.
EA200901421A1 (ru) Антитела к il-25
EA201892774A1 (ru) Антитела
NZ752706A (en) Dna-binding protein using ppr motif, and use thereof
MX2021001418A (es) Produccion de proteinas heteromultimericas usando celulas de mamifero.
WO2014151644A3 (en) Anti-cd52 antibodies
MX2020009550A (es) Proteinas de union a antigeno antagonistas.
WO2017040323A3 (en) Stabilized peptides for covalent binding to target protein

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18787597

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2019556608

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018787597

Country of ref document: EP

Effective date: 20191118

ENP Entry into the national phase

Ref document number: 3064852

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2018256237

Country of ref document: AU

Date of ref document: 20180418

Kind code of ref document: A